ArticleInvestigative ophthalmology & visual science2014
Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats.
Article in Investigative ophthalmology & visual science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03437759 (Mesenchymal Stem Cells Derived Exosomes Promote Healing of Large and Refractory Macular Holes), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mesenchymal Stem Cells Derived Exosomes Promote Healing of Large and Refractory Macular Holes
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies.Eye (London, England) · 2024Pooled it
- Review
- Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases.Extracellular vesicles and circulating nucleic acids · 2022Review
- Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.Frontiers in immunology · 2022Review
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases.Stem cell reviews and reports · 2021Review
- Subconjunctival injection of tumor necrosis factor-α pre-stimulated bone marrow-derived mesenchymal stem cells enhances anti-inflammation and anti-fibrosis in ocular alkali burns.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Mesenchymal stem cell-derived extracellular vesicles as a new therapeutic strategy for ocular diseases.World journal of stem cells · 2020Review
- Effect of Mesenchymal Stem Cell-Derived Exosomes on Retinal Injury: A Review of Current Findings.Stem cells international · 2020Review
- Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro.Veterinary ophthalmology · 2020Article
- A resistance-sensing mechanical injector for the precise delivery of liquids to target tissue.Nature biomedical engineering · 2019Article
- Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Perspectives of Autologous Mesenchymal Stem-Cell Transplantation in Macular Hole Surgery: A Review of Current Findings.Journal of ophthalmology · 2019Review
- The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.Frontiers in veterinary science · 2019Review
- Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018Article
- Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem Cell-Based Therapy for Autoimmune and Inflammatory Diseases.Frontiers in immunology · 2018Review
- Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.International journal of molecular sciences · 2017Review
- Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune Uveitis.Scientific reports · 2017Article
- Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.World journal of stem cells · 2017Review
- Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeWe tested the long-term effects of different regimens of mesenchymal stem cell (MSC) administration in a recurrent experimental autoimmune uveitis (rEAU) model in rats, and compared the efficacy of MSC to that of dexamethasone (DEX).
methodsOne or two courses of MSC treatments were applied to R16-specific T cell-induced rEAU rats before or after disease onsets. The DEX injections were given for 7 or 50 days continuously after disease onsets. Clinical appearances were observed until the 50th day after transfer. On the 10th day, T cells from control and MSC groups were analyzed by flow cytometry. Supernatants from the proliferation assay and aqueous humor were collected for cytokine detection. Functions of T cells and APCs in spleens also were studied by lymphocyte proliferation assays.
resultsOne course of MSC therapy, administered after disease onset, led to a lasting therapeutic effect, with a decreased incidence, reduced mean clinical score, and reduced retinal impairment after 50 days of observation, while multiple courses of treatment did not improve the therapeutic benefit. Although DEX and MSCs equally reduced the severity of the first episode of rEAU, the effect of DEX was shorter lasting, and DEX therapy failed to control the disease even with long periods of treatment. The MSCs significantly decreased T helper 1 (Th1) and Th17 responses, suppressed the function of antigen-presenting cells, and upregulated T regulatory cells.
conclusionsThese results suggested that MSCs might be new corticosteroid spring agents, while providing fewer side effects and longer lasting suppressive effects for recurrent uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.